Adrian Langleben

1.9k total citations · 1 hit paper
55 papers, 1.1k citations indexed

About

Adrian Langleben is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Adrian Langleben has authored 55 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Adrian Langleben's work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cancer Treatment and Pharmacology (10 papers). Adrian Langleben is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (11 papers) and Cancer Treatment and Pharmacology (10 papers). Adrian Langleben collaborates with scholars based in Canada, United States and South Korea. Adrian Langleben's co-authors include George Shenouda, Jean‐Guy Villemure, Alexander S. Rosemurgy, Jules E. Harris, Ephraim S. Casper, Henrik Rasmussen, Eleanor Elstein, Samy Suissa, Themistocles L. Assimes and Gordon H. Baltuch and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Adrian Langleben

52 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adrian Langleben Canada	17	725	416	316	167	158	55	1.1k
Edgardo S. Santos United States	21	576 0.8×	524 1.3×	384 1.2×	105 0.6×	230 1.5×	101	1.2k
Eugenio Villa Italy	14	676 0.9×	396 1.0×	215 0.7×	114 0.7×	157 1.0×	20	973
Jessica Read United Kingdom	9	733 1.0×	514 1.2×	428 1.4×	247 1.5×	165 1.0×	11	1.6k
Martin Wiesenfeld United States	19	626 0.9×	210 0.5×	273 0.9×	142 0.9×	177 1.1×	33	982
Francisco Javier Ramos Spain	15	625 0.9×	422 1.0×	771 2.4×	72 0.4×	192 1.2×	42	1.4k
Bradley G. Somer United States	16	808 1.1×	304 0.7×	412 1.3×	149 0.9×	279 1.8×	45	1.3k
Fabrice Branle Switzerland	15	951 1.3×	796 1.9×	578 1.8×	219 1.3×	209 1.3×	36	1.5k
Thomas Makatsoris Greece	22	1.0k 1.4×	338 0.8×	362 1.1×	59 0.4×	198 1.3×	85	1.5k
Dale R. Shepard United States	17	478 0.7×	470 1.1×	419 1.3×	60 0.4×	258 1.6×	75	1.2k
Teresa Alonso‐Gordoa Spain	19	619 0.9×	343 0.8×	366 1.2×	333 2.0×	239 1.5×	82	1.2k

Countries citing papers authored by Adrian Langleben

Since Specialization

Citations

This map shows the geographic impact of Adrian Langleben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrian Langleben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrian Langleben more than expected).

Fields of papers citing papers by Adrian Langleben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrian Langleben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrian Langleben. The network helps show where Adrian Langleben may publish in the future.

Co-authorship network of co-authors of Adrian Langleben

This figure shows the co-authorship network connecting the top 25 collaborators of Adrian Langleben. A scholar is included among the top collaborators of Adrian Langleben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrian Langleben. Adrian Langleben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gray, Jhanelle E., Michael Schenker, Mehmet Alı Nahıt Şendur, et al.. (2024). MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study. Journal of Thoracic Oncology. 19(10). S98–S98. 1 indexed citations

Gambaro, Karen, Maud Marques, Cyrla Hoffert, et al.. (2023). A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy. International Journal of Molecular Sciences. 25(1). 43–43.

Rodríguez‐Abreu, Delvys, Martin Reck, K. Park, et al.. (2022). 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 33. S30–S31. 2 indexed citations

Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338. 165 indexed citations breakdown →

Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598. Journal of Thoracic Oncology. 16(3). S61–S62.

Ferrario, Cristiano, Khashayar Esfahani, Adrian Langleben, et al.. (2016). Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. PLoS ONE. 11(12). e0167906–e0167906. 10 indexed citations

Langleben, Adrian, Jeffrey G. Supko, Sébastien J. Hotte, et al.. (2010). Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies. Cancer Research. 70(8_Supplement). LB–171. 1 indexed citations

Hoff, Paulo M., Scott Kopetz, Melanie B. Thomas, et al.. (2008). A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. British Journal of Cancer. 99(5). 722–726. 1 indexed citations

Sankar, Tejas, Zografos Caramanos, Rachid Assina, et al.. (2008). Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. Journal of Neuro-Oncology. 90(1). 63–76. 15 indexed citations

10.

Huang, Fleur, et al.. (2008). Prophylactic Cranial Irradiation in Advanced Breast Cancer: A Case for Caution. International Journal of Radiation Oncology*Biology*Physics. 73(3). 752–758. 26 indexed citations

11.

Hirsh, Vera, Renaud Whittom, Linda Ofiara, et al.. (2003). Weekly paclitaxel and gemcitabine chemotherapy for metastatic non‐small cell lung carcinoma (NSCLC). Cancer. 97(9). 2242–2247. 10 indexed citations

12.

Hirsh, Vera, et al.. (2001). Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma. Cancer. 92(4). 830–835. 16 indexed citations

13.

Muanza, Thierry, George Shenouda, Luís Souhami, et al.. (2000). High Dose Tamoxifen and Radiotherapy in Patients with Glioblastoma Multiforme: A Phase IB Study. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 27(4). 302–306. 14 indexed citations

14.

Rosemurgy, Alexander S., et al.. (1999). Marimastat in Patients With Advanced Pancreatic Cancer. American Journal of Clinical Oncology. 22(3). 247–252. 89 indexed citations

15.

Cutler, Corey, et al.. (1998). Pulmonary blastoma. Cancer. 82(3). 462–467. 45 indexed citations

16.

Roberts, James A., Eric L. Jenison, KyungMann Kim, Daniel L. Clarke‐Pearson, & Adrian Langleben. (1997). A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of ORG 2766 in the Prevention or Delay of Cisplatin-Induced Neuropathies in Women with Ovarian Cancer. Gynecologic Oncology. 67(2). 172–177. 47 indexed citations

17.

Crawford, Jeffrey, Mark Allen O’Rourke, Joan H. Schiller, et al.. (1996). Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer.. Journal of Clinical Oncology. 14(10). 2774–2784. 100 indexed citations

18.

Langleben, Adrian, et al.. (1995). A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 35(6). 496–500. 3 indexed citations

19.

Langleben, Adrian, et al.. (1988). Double antibody radioimmunoassay for monitoring metastatic breast cancer. British Journal of Cancer. 58(3). 362–367. 7 indexed citations

20.

Gulati, Subhash C., et al.. (1988). Comparative Regimens for the ex vivo Chemopurification of B Cell Lymphoma-Contaminated Marrow. Acta Haematologica. 80(2). 65–70. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact